IP Library Granted Patent US 9,822,339
Granted Patent B2
US 9,822,339 · App. 14/836,335 · Granted Nov 21, 2017

Means and methods for influencing the stability of antibody producing cells

Inventors: Hergen Spits (Amsterdam Zuidoost, NL); Ferenc A. Scheeren (Amsterdam, NL); Tim Beaumont (Amsterdam Zuidoost, NL); Sean A. Diehl (Shelburne, VT)
Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM; AIMM THERAPEUTICS B.V.
C12N5/0635C07K16/00C12N2501/23C12N2501/231C12N2501/2321C12N2501/52C12N2501/60C12N2502/99C12N2510/02C12N2510/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,339
App. No.
14/836,335
Granted
Nov 21, 2017
Kind
B2
Abstract

The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

Claims (12)

1. An antibody producing B cell culture, comprising:

at least one of IL-21 and/or IL-10; and

B cells, said B cells comprising an exogenous nucleic acid sequence, said exogenous nucleic acid sequence encoding a peptide comprising Bcl6, or a functional part thereof, capable of increasing the replicative life span of an antibody producing B cell.

2. The antibody producing B cell culture according to claim 1 , wherein the B cells further comprise an exogenous anti-apoptotic nucleic acid sequence.

3. The antibody producing B cell culture according to claim 2 , wherein the exogenous anti-apoptotic nucleic acid sequence encodes a member of the anti-apoptotic Bcl 2 family.

4. The antibody producing B cell culture according to claim 2 , wherein the exogenous anti-apoptotic nucleic acid sequence encodes a peptide comprising Bcl-xL, or a functional part thereof, capable of increasing the replicative life span of an antibody producing B cell.

5. The antibody producing B cell culture according to claim 4 , wherein expression of the nucleic acid sequence encoding Bcl6 or Bcl-xL, or a functional part of Bcl6 or Bcl-xL, is regulated by at least one of an activator and/or repressor that is inducible by an exogenous compound.

6. The antibody producing B cell culture according to claim 1 , wherein the B cells further comprise an exogenous compound capable of directly or indirectly enhancing Bcl xL expression.

7. The antibody producing B cell culture according to claim 6 , wherein the compound comprises at least one of APRIL, BAFF, CD40, BCR stimulation, cytokines, growth factors or downstream effector(s).

8. The antibody producing B cell culture according to claim 1 , wherein the B cells are capable of replicating for at least nine weeks.

9. The antibody producing B cell culture according to claim 1 , wherein the B cells are capable of producing antibodies against an antigen of interest.

10. The antibody producing B cell culture according to claim 9 , wherein the B cells are derived from an individual, which individual had been previously exposed to said antigen of interest.

Assignments (4)
CHANGE OF NAME Recorded Dec 9, 2024
From: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
To: STICHTING AMSTERDAM UMC
Reel/Frame 069536/0408 →
CHANGE OF NAME Recorded Sep 11, 2024
From: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
To: STICHTING AMSTERDAM UMC
Reel/Frame 071410/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: AIMM THERAPEUTICS B.V.
To: KLING BIOTHERAPEUTICS B.V.
Reel/Frame 055711/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2015
From: SPITS, HERGEN; BEAUMONT, TIM; DIEHL, SEAN A.; SCHEEREN, FERENC A.
To: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM; AIMM THERAPEUTICS B.V.
Reel/Frame 036428/0799 →
Priority Claims (2)
NL PCT/NL2005/000848 · Dec 9, 2005 · national
EP 06076211 · Dec 6, 2006 · regional
Continuity (2)
Division 12086328
Related Publication 20160060598A1 · Mar 3, 2016